Skip Navigation

European Heart Journal 2002 23(16):1233-1237; doi:10.1053/euhj.2002.3246
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by White, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, H. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Further evidence that antithrombotic therapy is beneficial with streptokinase: improved early ST resolution and late patency with enoxaparin

Harvey D. White

Cardiology Department, Green Lane Hospital, Auckland, New Zealand

References

  1. Simoons ML, Krzemiñska-Pakula M, Alonso A. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction; the AMI–SK study. Eur Heart J. 2002;23:1282–1288[Abstract/Free Full Text]
  2. Ross AM, Molhoek P, Lundergan C. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. 2001;104:648–652[Abstract/Free Full Text]
  3. Antman EM, Louwerenburg HW, Baars HF. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation. 2002;105:1642–1649[Abstract/Free Full Text]
  4. de Lemos JA, Antman EM, Giugliano RP. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Am J Cardiol. 2000;85:299–304[CrossRef][ISI][Medline]
  5. Lancet. 2001;358:605–613[CrossRef][ISI][Medline]
  6. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol. 1997;30:962–969[Abstract]
  7. Frostfeldt G, Ahlberg G, Gustafsson G. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction—a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol. 1999;33:627–633[Abstract/Free Full Text]
  8. Wallentin L, Dellborg DM, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol. 2001;24:I-12–I-14[ISI][Medline]
  9. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease (FRISC II) Investigators, Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study [published erratum appears in Lancet, 1999; 354: 1478], Lancet, 1999, 354, 701, 7
  10. Ryan TJ, Antman EM, Brooks NH. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34:890–911[Free Full Text]
  11. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest. 1992;101:131S–139S[Abstract/Free Full Text]
  12. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997;336:847–860[Free Full Text]
  13. N Engl J Med. 1993;329:673–682[Abstract/Free Full Text]
  14. Hsia J, Hamilton WP, Kleiman N. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433–1437[Abstract]
  15. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:1412–1417[CrossRef][ISI][Medline]
  16. Tardiff BE, McCants B, Hellkamp AS. Long term results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial: sustained benefit of fibrin-specific therapy [abstract]. Circulation. 1999;100:I-498–I-499
  17. N Engl J Med. 1993;329:1615–1622[Abstract/Free Full Text]
  18. Antman EM, Giugliano RP, Gibson CM. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720–2732[Abstract/Free Full Text]
  19. White HD. Future of reperfusion therapy for acute myocardial infarction [editorial]. Lancet. 1999;354:695–697[CrossRef][ISI][Medline]
  20. Van de Werf F, Barron HV, Armstrong PW. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rtPA. Eur Heart J. 2001;22:2253–2261[Abstract/Free Full Text]
  21. Circulation. 2000;101:2788–2794[Abstract/Free Full Text]
  22. Lancet. 2001;357:1905–1914[CrossRef][ISI][Medline]
  23. Hudson MP, Granger CB, Topol EJ. Early reinfarction after fibrinolysis: experience from the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) trials. Circulation. 2001;104:1229–1235[Abstract/Free Full Text]
  24. van Domburg RT, Deckers JW, van Bergen PFMM, Azar AJ, Jonker JJC, Simoons ML. Prognostic significance of nonfatal myocardial reinfarction in survivors of a first infarction. Netherlands Heart Journal. 2001;9:166–172
  25. Lancet. 2001;358:1855–1863[CrossRef][ISI][Medline]
  26. Grines CL, Ellis S, Jones M. Primary coronary angioplasty vs. thrombolytic therapy for treatment of acute myocardial infarction (MI). Findings from the PCAT collaboration [abstract]. Eur Heart J. 1999;20:170[ISI][Medline]
  27. Andersen, HR, The Danish Multicenter Randomized Study on Thrombolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2)
  28. Grines CL, Cox DA, Stone GW. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999;341:1949–1956[Abstract/Free Full Text]
  29. Stone GW, Grines CL, Cox DA. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957–966[Abstract/Free Full Text]
  30. Montalescot G, Barragan P, Wittenberg O. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–1903[Abstract/Free Full Text]
  31. Lee Y-K, Nam JH, Shin H-C, Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation. 2001;104:3116–3120[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
American College of Cardiology/American Heart Asso, Developed in Collaboration With the Canadian Cardi, Endorsed by the American Academy of Family Physici, 2007 Writing Group to Review New Evidence and Upda, E. M. Antman, M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, et al.
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
J. Am. Coll. Cardiol., January 15, 2008; 51(2): 210 - 247.
[Full Text] [PDF]

Home page
 CirculationHome page
E. M. Antman, M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, J. S. Hochman, H. M. Krumholz, G. A. Lamas, C. J. Mullany, et al.
2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee
Circulation, January 15, 2008; 117(2): 296 - 329.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. S Kalus and L. R Moser
Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction
Ann. Pharmacother., March 1, 2005; 39(3): 481 - 491.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by White, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, H. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?